Physician Assistant evaluation for quality assurance in the drug therapy of prostate cancer through the recording of symptoms and quality of life with the support of artificial intelligence
- Conditions
- C61Malignant neoplasm of prostate
- Registration Number
- DRKS00029278
- Lead Sponsor
- niversitätsklinikum HeidelbergMedizinische Onkologie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 20
• male patients over 18 years of age
• histologically confirmed prostate cancer
• indication for the drug treatment of prostate cancer, e.B. with antihormonal therapy, chemotherapy or targeted therapy
• an expected observation period of 16 weeks from the start of therapy
• Written inform of consent
• the patient must have his own privately used smartphone - Android, iOS or tablet
• Readiness and sufficient knowledge to be able to use the app
• Sufficient German language skills, if possible native language level
• Inability to give written consent to the participation in the study
• ECOG > 2
• Severely impaired vision or hearing
• Existence of a clinically relevant psychiatric or neurological disorder
• Absent of inform of consent for the collection, documentation and evaluation of personal and disease-related data in the electronic database while ensuring all legal data protection regulations
• Current participation in another study for which participation in this study is an exclusion criterion (e.B. therapy study)
• Study participation in clinically relevant second malignancy at investigator's discretion
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method